Cabaletta Bio Reports Positive Rese-cel Data Across Myositis, SSc, and SLE Trials

Cabaletta Bio Inc. (NASDAQ:CABA) is one of the best stocks under $3 to invest in. On October 27, Cabaletta Bio announced positive clinical data and development updates for its investigational targeted cell therapy, rese-cel (resecabtagene autoleucel, formerly known as CABA-201), across its RESET-Myositis, RESET-SSc, and RESET-SLE trials.

As of October 24, the overall RESET program had 76 patients enrolled across 77 clinical trial sites globally. Rese-cel is an autologous CAR T cell therapy engineered to transiently and deeply deplete CD19-positive cells using a single, weight-based infusion, aiming for durable, drug-free clinical responses.

Based on initial data from 3 patients in the RESET-PV trial, suggesting potentially complete B cell depletion is possible with rese-cel without the need for a fludarabine and cyclophosphamide lymphodepleting preconditioning regimen, Cabaletta is expanding this no preconditioning approach into the RESET-SLE trial. A new dose-escalation cohort will be incorporated into the lupus trial to provide a simpler, patient-focused alternative, especially for women of childbearing potential. Initial clinical data from this no preconditioning cohort are anticipated in 2026.

Cabaletta Bio Inc. (NASDAQ:CABA) is a clinical-stage biotechnology company that discovers and develops engineered T cell therapies for patients with autoimmune diseases.

While we acknowledge the potential of CABA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.